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Table 1
IFN-g+CD4+ T cells
among viable CD4+ T
lymphocytes (n¼6)
IFN-g+CD8+ T cells
among viable CD8+ T
lymphocytes (n¼6)
Pre-enrichment (%) 0.07 (0.03 e 0.61) 0.43 (0.07 e 0.56)
Post-enrichment (%) 62.20 (14.73 e 91.39) 89.36 (61.59 e 94.20)
Mean Yield / 109
starting TNCs
1.5x105 1.5x105
Abstracts / Biol Blood Marrow Transplant 20 (2014) S128eS150 S137kg child this yields 4x103 and 104 cells/kg, respectively, of
pathogen-speciﬁc T cells, which is consistent with the
numbers needed to treat chemotherapy-refractory CMV in
clinical trials using the ﬁrst generation technology. We are
implementing a pre-screening approach to identify CMV
seropositive donors that may fail to collect and extending our
evaluation of the Prodigy system to capture pathogen-spe-
ciﬁc T cells with speciﬁcity other than CMV. These data
demonstrate automated production of CMV-speciﬁc T cells is
feasible and will enable investigators to produce clinical-
grade pathogen speciﬁc allogeneic T cells for add-back after
HSCT at multiple points-of-care broadening the application
of this promising immunotherapy.HISTOCOMPATIBILITY/ALTERNATIVE STEM CELL SOURCES188
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Background: The safety and efﬁcacy of UCB as a donor
source for hematopoietic stem cell (HSC) transplantation is
well established (Wagner/Cairo et al, Blood, 1996; Kurtzberg
et al, NEJM,1996). Further, the naiveté of these cells allows for
greater HLA mismatch and leads to decreased rates of
chronic GVHD (Liao/Cairo et al, Exp Hem,2011). However, the
number of HSC’s in each UCB unit is signiﬁcantly less than
that obtained from peripheral blood and bone marrow
(Cairo/Kurtzberg et al, Transfusion, 2005), prolonging time to
engraftment (Cairo et al, Blood,1997). With longer periods of
neutropenia increasing the risk of infectious complications in
UCB transplantation, much effort has been made to improve
time to engraftment in UCB transplants. One strategy
developed by Cellgene Cellular Therapeutics (CCT) is co-
infusion of UCB with HPDSC’s. HPDSC’s, derived from CCT’s
proprietary process, represent a more immature HSC source,
containing a higher concentration of CD34+ cells as well as
CD34+/CD45- cells than UCB. Augmenting the graft with
early progenitors may increase the engraftment potential of
UCB. Studies using a NOD/SCID mouse model demonstrate
earlier engraftment when HPDSC’s are combined with UCB
transplant and increased engraftment compared to UCB or
HPDSC’s alone.
Objective: To determine the feasibility and safety of com-
bined UCB transplantationwith HPDSC’s usingmyeloablative
or reduced intensity conditioning for malignant and non-
malignant diseases.
Methods: We have developed a multicenter consortium
(CCT-HPDSC-UCBT-PI-001) to investigate this approach
(Figure1A). Patients with eligible malignant and non-malig-
nant diseases who have a single or double UCB donor (4/6-6/and CBT clinical trial and (B) the overall treatment plan.
Patient Age at Time of
Transplant (years)
# UCB
Units
HLA
Match
CD34/kg Status Time to Neutrophil Engraftment
(ANC>500/mm3)
Maximum
Grade aGVHD
% Donor Peripheral Blood
Chimersim/Day
NYMC-
550-
001
11.2 1 Unit 1:
6/6
Unit 1:
2.78105
Alive day
+170
53 days None to date 99% donor 1 Day+100
NYMC-
550-
002
22.5 2 Unit 1:
5/6
Unit 2:
5/6
Unit 1:
1.93105
Unit 1:
1.42105
Alive day
+108
23 days None to date 28% donor 1, 72% donor 2
Day +100
NYMC-
550-
003
17.8 2 Unit 1:
4/6
Unit 2:
4/6
Unit 1:
3.58105
Unit 1:
2.51105
Alive day
+52
14 days None to date 59% donor 1, 41% donor 2
Day +30
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107 /kg either alone or combined are eligible. The experi-
mental design is depicted in Figure 1B.
Results: To date 3 patients have been transplanted on this
protocol. 1 received a single UCB unit for adrenoleukodys-
trophy (ALD) and 2 received double UCB transplants for acute
lymphoblastic leukemia (ALL). Pre-thaw TNC/kg of HPDSC
were 5.6 x106, 3.9 x106, and 3.1 x106 for patients 1-3
respectively. The characteristics of the pre-thaw UCB are
summarized in Table 1. All 3 patients are alive at 52-170 days
post-transplant with no acute GVHD observed to date and
time to neutrophil engraftment ranging from 14-53 days. In
each case, host and HPDSC chimerisms diminished to low or
undetectable levels over time, but mixed chimerism has
persisted in the double cord blood transplants as far out as
day +100. These results are further summarized in Table 1.
Summary: These data suggest that UCB transplantation in
conjunction with HPDSC infusion is safe and well tolerated
for children with malignant and nonmalignant diseases. A
larger cohort and longer follow-up will be required to
determine the safety and clinical signiﬁcance of these early
ﬁndings. (NCT01586455).189
Double-Unit Cord Blood (CB) Transplantation Combined
with Haplo-Identical CD34+ Cells Results in 100% CB
Engraftment with Enhanced Myeloid Recovery
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Day +14
Whole PB
(n[ 15)
Day +28
PB Subsets
(n[ 15)
Dominant
CB Unit
17%
(0-100)
Neut: 85%
(0-100)
T: 100%
(0-100)
Non-
Engrafting
CB Unit
0%
(0-11)
Neut: 0%
(0-22)
T: 0%
(0-100)
Haplo-
Donor
77%
(0-100)
Neut: 0%
(0-100)
T: 0%
(0-19)
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Background: Double-unit CB transplantation (DCBT) has
provided high rates of sustained donor engraftment. How-
ever, delayed engraftment is frequent & is associated with
increased transplant-related mortality (TRM).
Methods:We investigated the combined transplantation of a
4-6/6 double-unit CB allograft (infused day 0) with periph-
eral blood derived Miltenyi CD34+ selected haplo-identical
stem cells (haplo-CD34+, infused day 0 or +1) to speed
myeloid recovery. DCB grafts were used to facilitate com-
parison with DCB only controls.
Results: Of 23 eligible patients, 6/23 (26%) had no suitable
haplo-identical donor. Thus, 17 patients (median 39 years,
range 16-69) were transplanted 9/2012-6/2013 with DCB
plus haplo-CD34+ cells for high-risk hematologic malig-
nancies. Conditioning was myeloablative with CSA/MMF
immunosuppression. Median infused CB TNC x 107/kg was
2.29 (larger unit) & 1.82 (smaller unit). 15 patients received 3
x 106/kg CD34+ cells (the targeted dose) whereas 2 each
received 1 x 106/kg. The median infused haplo-CD3+ dose
was 0.6 x 103/kg (range 0.3-1.6). One patient died on day 14.
Of 16 evaluable patients, all (100%) engrafted. The median
neutrophil recovery was 13.5 days (range 11-31) in 14ange)
Day +60
Whole PB
(n[ 13)
Day +100
PB Subsets
(n[ 13)
Day +180
Whole PB
(n[ 9)
100%
(34-100)
Neut:100%
(77-100)
T: 100%
(50-100)
100%
(all 100)
0%
(0-25)
Neut: 0%
(0-20)
T: 0%
(0-50)
0%
0%
(0-66)
Neut: 0%
(0-23)
T: 0%
(0-1)
0%
